Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

Go To Global Site
Welcome to UCB in the United States

R&D pipeline

The UCB pipeline delivers:

  • a promising portfolio targeting severe diseases and addressing unmet medical needs
  • focus on neurological and immunological diseases
  • more convenient and effective treatments for patients and specialists.

UCB is connecting science in new ways to illuminate the biological pathways involved in severe diseases. Our researchers are developing a range of novel chemical entities (NCEs) and novel biological entities (NBE) to improve people’s lives.

Small molecule drug / NCE

 Neurology

Antibody-based drug / NBE

 Immunology

 

  Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF) psoriasis
  psoriatic arthritis
  axial spondyloarthritis
  hidradenitis suppurativa
rozanolixizumab (FcRn) myasthenia gravis
  immune thrombocytopenia
  chronic inflammatory demyelinating polyneuropathy (CIDP)
zilucoplan (C5) myasthenia gravis
  immune-mediated necrotizing myopathy (IMNM)
  amyotrophic lateral sclerosis1
  COVID-associated acute respiratory distress syndrome (ARDS)2
Staccato® alprazolam active epileptic seizure
dapirolizumab pegol (CD40L) systemic lupus erythematosus3
UCB0107 (Tau) progressive supranuclear palsy (PSP)
1 Project  
1 Project  

 

1 In partnership with HEALEY ALS Platform Trial
2 In partnership with University of Ghent (Belgium) & Medical Research Council (U.K.)
3 In partnership with Biogen

 

Information provided on this pages represents molecules currently under investigation and are not approved by any health authority worldwide.

 

Products
U.S. Clinical Trials
U.S. Innovation

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)